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RESUMEN
La esterificación de ácido oleico en policosanoles 
aumenta su biodisponibilidad y el efecto hipocolestero-
lémico en ratas
Los Policosanoles están formados por una mezcla de al-
coholes alifáticos de cadena larga y se obtienen de las ceras 
de la caña de azúcar. Más de cincuenta estudios indican que 
los policosanoles reducen el colesterol sérico, mientras que 
otros no logran reproducir este efecto. El objetivo de esta in-
vestigación fue evaluar la biodisponibilidad de policosanoles 
esterificados y no esterificados (NEP), en relación con sus 
efectos hipocolesterolémicos. Para ello, a ratas Sprague 
Dawley se les administró una dosis oral diaria de 100 mg kg–1 
de NEP, 117 mg kg–1 de policosanoles esterificados con 
ácido butírico (BAEP), ó 164 mg kg–1 de policosanoles esteri-
ficados con ácido oleico (OAEP). La absorción de los polico-
sanoles se evaluó en el plasma entre 0 y 3 horas después de 
la ingestión. Para evaluar los cambios en el colesterol total, 
colesterol-LDL, colesterol-HDL y triglicéridos en el plasma y 
en la fosforilación de la hígado 3-hidroxi-3-metilglutaril coen-
zima A reductasa (HMG-CoA red), la ingesta de las ratas fue 
suplementada con policosanoles no esterificados o esterifi-
cados durante 5 semanas. Los resultados indicaron que la 
absorción de los policosanoles fue significativamente mayor 
en las ratas tratadas con los OAEP que en las sometidas a 
los NEP o las que se les administró BAEP. Los OAEP redu-
jeron significativamente el colesterol plasmático total y el co-
lesterol-LDL de las ratas, además de aumentar 5.6 veces 
(P < 0,05) sobre los valores control, en el contenido hepático 
de la HMG-CoA fosforilada red. En conclusión, la esterifica-
ción de policosanoles con ácido oleico aumenta la biodispo-
nibilidad de los policosanoles, y mejora significativamente el 
perfil de lípidos séricos en ratas normocolesterolémicos en 
asociación con la inactivación de la colesterogénesis control 
HMG-CoA red. 
PALABRAS-CLAVE: Absorción de Policosanoles – Bio-
disponibilidad – Efecto reductor de colesterol – Octacosanol 
– Policosanol – Triacontanol – Ratas.
SUMMARY
The oleic acid esterification of policosanol increases 
its bioavailability and hypocholesterolemic action in rats
Policosanol comprises a mixture of long-chain aliphatic 
alcohols from sugarcane wax. More than 50 studies indicate 
that policosanol decreases serum cholesterol, while others 
failed to reproduce this effect. The objective of this investigation 
was to assess the bioavailability of esterified policosanol 
and non-esterified policosanol (NEP), in relation to their 
hypocholesterolemic effects. Sprague Dawley rats were given 
a daily oral dose of 100 mg/kg of NEP, 117 mg kg–1 of butyric 
acid esterified policosanol (BAEP), or 164 mg kg–1 of oleic acid 
esterified policosanol (OAEP). Policosanol absorption was 
evaluated in plasma between 0 and 3 hours after ingestion. To 
assess changes in total cholesterol, LDL-cholesterol, HDL-
cholesterol and triacylglycerols in plasma and liver 3-hydroxy-
3-methylglutaryl coenzyme A reductase (HMG- CoA red) 
phosphorylation, the rats were supplemented with non-
esterified or esterified policosanol for 5 weeks. The results 
indicate that policosanol absorption was significantly greater in 
OAEP-treated rats than in those subjected to NEP or BAEP 
administration. OAEP significantly reduced plasma total and 
LDL-cholesterol in rats, in addition to a 5.6-fold increase 
(P < 0.05) in the hepatic content of phosphorylated HMG-CoA 
red over the control values. In conclusion, esterification of 
policosanol with oleic acid enhances policosanol bioavailability, 
and significantly improves the serum lipid profile in 
normocholesterolemic rats in association with the inactivation 
of HMG-CoA red controlling cholesterogenesis.
KEY-WORDS: Bioavailability – Cholesterol lowering 
effect – Octacosanol – Policosanol – Policosanol absorption 
– Rats – Triacontanol.
1. INTRODUCTION
Coronary heart disease is a leading cause of 
death in industrialized nations, with elevated levels 
of total serum cholesterol, low density lipoprotein 
346 grasas y aceites, 63 (4), octubre-diciembre, 345-354, 2012, issn: 0017-3495, doi: 10.3989/gya.010612
D. HAIM, A. VALENzUELA, M. C. BrAñES, M. FUENzALIDA AND L. A. VIDELA
(LDL)-cholesterol, and triglycerides, as important 
cardiovascular risk factors (Singh and Mehta, 
2002). Policosanol, a mixture of primary aliphatic 
alcohols originally derived from sugarcane 
wax (Saccharum officinarum) (Janikula, 2002), in 
which octacosanol (63%), triacontanol (13%) and 
hexacosanol (6%) prevail (Gouni-Berthold et al., 
2002), effectively improves serum lipid profiles. 
This effect was shown in animal models (Menéndez 
et al., 1996; Arruzazabala et al., 2000), healthy 
human subjects (Hernández et al., 1992), and 
patients with either type II hypercholesterolemia 
(Pons et al., 1992; Batista et al., 1996; Mas et al., 
1999; Castaño et al., 2001), type II diabetes (Torres 
et al., 1995; Crespo et al., 1999), or postmenopausal 
women (Castaño et al., 2000). Interestingly, 10 mg 
of this mixture had similar efficacy to an equivalent 
dose of statins in lowering the serum LDL 
concentrations (Castaño et al., 1999; Prat et al., 
1999), and its supplementation caused a significant 
increase in the fecal excretion of neutral and acidic 
sterols in hamsters (Ng et al., 2005), whereas 
octacosanol administration to humans decreased 
bile acid concentration in feces (Keller and 
Gimmler, 2008). Various studies have suggested 
an inhibition of the enzyme which limits the 
cholesterogenic route, 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMG-CoA red) (Singh 
et al., 2006; Menendez et al, 2001; Oliaro-Bosso 
et al., 2009), as the mechanism of action of 
policosanol hypocholesterolemic activity. However, 
recent clinical trials failed to show significant 
effects. In fact, no changes in lipid variables in 
subjects receiving policosanol were reported 
(Greyling et al., 2006; Berthold et al., 2006; 
Dulin et al., 2006; Kassis and Jones, 2006) and 
neither primary hypercholesterolemic subjects 
(Francini-Pesenti et al., 2008a) nor diet-resistant 
hypercholesterolemic patients (Francini-Pesenti et 
al., 2008b) were affected by policosanol treatment 
for 8 weeks.
In the context of bioavailability of policosanols, few 
investigations have been performed. In nature, fatty 
alcohols comprising policosanol are esterified (wax), 
but the extraction process releases the fatty alcohols 
from the wax (Haim and Videla, 2008). These forms 
of non-esterified policosanol (NEP) were used in all 
the reported studies, including those of bioavailaibility 
assessment (Marrero and González-Bravo, 2001; 
Menéndez et al., 2005). These two reports involve 
validation of an analytical method using a maximum 
octacosanol plasma concentration of 14 ng mL–1 after 
a single oral dose of 40 mg policosanol kg–1 (Marrero 
and Gonzalez-Bravo, 2001) and an in vivo study of 
octacosanol metabolism detecting 30 ng octacosanol 
mL–1 plasma after a 60 mg/kg dose (Menéndez et al., 
2005), thus revealing a rather low absorption of 
policosanol given as non-esterified compounds. 
In view of these considerations, we have 
hypothesized that a potential explanation for the 
discrepancies reported in the field may be related 
to the insufficient absorption of NEP. Consequently, 
the aims of this study were to determine the role of 
policosanol esterification in the bioavailability and 
hypocholesterolemic effect of these compounds in 
rats. For these purposes, first, pharmacokinetic 
studies of policosanol administered as (i) NEP, (ii) 
butyric acid esterified policosanol (BAEP), and (iii) 
oleic acid esterified policosanol (OAEP) were 
assessed by quantifying plasma octacosanol, 
triacontanol, and their main metabolites in vivo 
(octacosanoic acid and triacontanoic acid) after a 
single oral dose. Then, total cholesterol, LDL-
cholesterol, and HDL-cholesterol concentrations in 
plasma were determined in rats supplemented with 
non-esterified and esterified policosanol for 5 
weeks, in addition to the hepatic content of total 
and phosphorylated HMG-CoA red controlling 
cholesterogenesis.
2. MATERIALS AND METHODS
2.2. Synthesis of esterified policosanol
Preparation of BAEP and OAEP. A policosanol 
mixture of 96% purity (62% octacosanol, 19% 
triacontanol) was purchased from Pharmapia 
International (Shanghai, China). Fatty acids, butyric 
acid (99%) and oleic acid (90%), were purchased 
from Sigma Aldrich Co. (St. Louis, MO, USA). The 
preparations of BAEP and OAEP were made by 
mixing policosanol with the respective fatty acid 
(20% excess related to policosanol) in the presence 
of 0,5% sulfuric acid (J.T. Baker, Phillipsburg, NJ, 
USA) at 150 °C. The concentration of NEP in the 
products of the reaction was less than 2% (detected 
by gas chromatography (model 7890A, Agilent 
Technologies, California, USA) coupled with an 
inert mass spectrometry detector (model 5975C, 
Agilent Technologies, California, USA)). 
Purification of esterified policosanol. The products 
of the esterification reaction were subjected to 
neutralization with KOH (J.T. Baker, Phillipsburg, 
NJ, USA) dissolved in ethanol/distilled water (1/1) 
for 1 h at 30 °C (ethanol was purchased from Merck 
KGaA, Darmstadt, Germany). Then the sample 
was subjected to liquid-liquid (distilled water-
heptane) separation, removing the organic phase 
which contained the esterified policosanol (heptane 
was purchased from Merck KGaA, Darmstadt, 
Germany). Qualitative and quantitative analyses 
were applied to esterified policosanols, verifying the 
structure and proportionality of the alcohols of the 
mixture in the esterified product.
Preparation of the policosanol dispersions. For 
oral administration to rats, 3 dispersions in water at 
10% p/v were prepared: a) NEP, b) BAEP, and c) 
OAEP. The surfactants used were Tween-20 and 
Span-85 at 5% based aqueous solution. Both 
surfactants were purchased from Sigma Aldrich Co. 
(St. Louis, MO, USA).
2.3. In vivo studies
Animal treatments. Male Sprague Dawley rats 
(Bioterio Central, Faculty of Medicine, University of 
grasas y aceites, 63 (4), octubre-diciembre, 345-354, 2012, issn: 0017-3495, doi: 10.3989/gya.010612 347
THE OLEIC ACID ESTErIFICATION OF POLICOSANOL INCrEASES ITS BIOAVAILABILITy AND HyPOCHOLESTErOLEMIC…
Chile, Santiago, Chile) were kept in a temperature 
and light controlled room (20 °C and a 12-h light-
dark cycle) and fed with a standard solid diet 
(Alimentos Champion, Santiago, Chile) and tap 
water ad libitum. rats employed for bioavailability 
assessment weighing 150-180 g and fasted 
overnight (12 h), were given a single oral dose of 
Tween-20/Span-85 water vehicle suspensions of 
NEP (100 mg kg–1 body weight), BAEP (117 
mg kg1), or OAEP (164 mg kg–1). The animals used 
in the chronic treatment with an initial body weight 
of 50-70 g, received either daily oral isovolumetric 
amounts of Tween-20/Span-85 water vehicle 
suspension alone (controls) or containing NEP (100 
mg kg–1) or OAEP (164 mg kg–1) for 5 weeks. 
Blood and liver samples. Blood samples for 
pharmacokinetic studies and assessment of lipid 
parameters were taken under anesthesia (zoletil, 
1 mL kg–1 body weight, Virbac Laboratory, Carros, 
Francia) by exsanguinations through cardiac 
puncture using heparinized tubes, and plasma was 
obtained by centrifugation (800 g for 10 min at 4 °C) 
and stored at –80 °C in aliquots of 20 µL until 
analysis. Liver samples were taken, frozen in liquid 
nitrogen, and kept at –80 °C for HMG-CoA red 
assessment. The study protocol was approved by 
the Bioethics Committee of the Faculty of Medicine, 
University of Chile (CBA #0325 FMUCH).
2.4.  Bioavailability of policosanol and long-
chain fatty acids
Determination of plasmatic NEP. The presence 
of non-esterified octacosanol and non-esterified 
triacontanol in plasma was investigated. The 
determination was carried out by adding the internal 
standard betulin (99% GC purity, Sigma Aldrich Co., 
St. Louis, MO, USA) to 100 mL of plasma, followed 
by sample desolventization under a nitrogen stream. 
After exhaustive evaporation, the residue was 
reconstituted in 100 µL of the derivatizing agent 
MSTFA (Sigma Aldrich Co, St. Louis, MO, USA) for 
20 min at 80 °C. Finally 0.5 µL were injected 
automatically into the gas chromatography (model 
7890A, Agilent Technologies, California, USA) 
coupled with an inert mass spectrometry detector 
(model 5975C, Agilent Technologies, California, 
USA) for quantitative analysis. The chromatographic 
conditions were described by Haim et al. (2009).
Determination of plasmatic total policosanol and 
long-chain fatty acids (non-esterified + esterified 
analyte). Total concentrations in plasma were 
determined for octacosanol, triacontanol, octacosanoic 
acid, and triacontanoic acid. The protocol included 
saponification and acidification of the sample, stages 
that hydrolyze the esters and reconstitute the fatty 
acids, respectively. Therefore, the technique allowed 
for the measuring of esterified and non-esterified 
analytes present in the plasma. The detailed 
methodology and validation of the technique were 
reported by our group (Haim et al., 2009).
2.5. Lipid analysis
Fasting plasma samples were drawn from 
control rats and animals subjected to NEP or OAEP 
supplementation for 5 weeks. Total cholesterol, 
LDL-cholesterol, HDL-cholesterol and triglyceride 
concentrations in plasma were measured with 
enzymatic kits and standardized reagents (Valtek 
Diagnostics, Santiago, Chile), and results were 
expressed as mg dL–1.
2.6.  Western blot analysis of HMG-CoA 
reductase
Liver samples (100-500 mg) frozen in liquid 
nitrogen were homogenized and suspended in a 
buffer solution pH 7.9 containing 10 mM HEPES, 1 
mM EDTA, 0.6% Nonidet P-40, 150 mM NaCl, and 
protease inhibitors (1 mM phenylmethylsulfonyl 
fluoride, 1 µg mL–1 aprotinin, 1 µg mL–1 leupeptin, 
and 1 mM orthovanadate). Soluble protein fractions 
(60 µg) were separated on 12% polyacrylamide gels 
using SDS-PAGE (Laemmli, 1970) and transferred 
to nitrocellulose membranes (Towbin et al., 1979), 
which were blocked for 1 hour at room temperature 
with TBS-containing 5% bovine serum albumin. The 
blots were washed with TBS–containing 0.1% 
Tween 20 and hybridized with either rabbit polyclonal 
antibodies for HMG-CoA red, phospho-HMG-CoA 
red (Ser 872) (Millipore, MA,USA), or mouse 
monoclonal antibody for b-actin (ICN Biomedicals, 
Inc., Aurora, OH, USA). After extensive washing, the 
antigen-antibody complexes were detected using 
horseradish peroxidase goat anti-rabbit IgG or goat 
anti-mouse IgG and a SuperSignal West Pico 
Chemiluminescence kit detection system (Pierce, 
rockford, IL).
2.7. Statistical analysis
The values shown represent the mean ± standard 
error of the mean (SEM) for the number of separate 
experiments indicated. One-way or two-way ANOVA 
followed by Newman-Keuls post-test assessed the 
statistical significance of difference among values. 
P values < 0.05 were considered significant. All 
statistical analyses were performed using GraphPad 
Prism software (version 4.0, GraphPad Software 
Inc., San Diego, CA, USA). 
3. RESULTS
3.1.  The effect of NEP administration on 
non-esterified policosanol and total 
policosanol (non-esterified + esterified) 
concentrations in plasma
The administration of NEP (100 mg kg–1) to rats 
did not increase the plasmatic concentrations 
of non-esterified alcohols, ranging from 3.79 ± 0.40 
to 4.70 ± 0.81 ng mL–1 for octacosanol (Fig. 1A) 
and from 1.34 ± 0.04 to 2.13 ± 0.21 ng mL–1 for 
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triacontanol (Fig. 1B), respectively. Conversely, the 
total policosanol in plasma significantly increased 
at min 60 compared with time zero (496 ± 25 
compared with 170 ± 9 ng mL–1 for octacosanol 
(Fig. 1A) and 130 ± 11 compared with 27 ± 5 ng mL–1 
for triacontanol (Fig. 1B), respectively). Esterified 
policosanol concentrations were calculated as 
the subtraction between total and non-esterified 
policosanol values. At time zero (fasting plasma 
samples without policosanol administration), 2.3% 
of total circulating octacosanol was detected as 
non-esterified alcohol, whereas the remaining 
fraction (97.7%) represented esterified octacosanol 
(Fig. 1A, inset). As expected, the proportions were 
similar for triacontanol (5% non-esterified and 95% 
esterified alcohol) (Fig. 1B, inset). Consequently, 
policosanol circulates predominantly in its esterified 
form.
3.2.  Comparison of plasma total policosanol 
concentrations in rats subjected to a 
single dose of NEP, BAEP, and OAEP
Fasting plasma samples were obtained after the 
administration of a single, oral dose of NEP, BAEP, 
or OAEP, and the kinetics of octacosanol (Fig. 2A), 
octacosanoic acid (Fig. 2B), triacontanol (Fig. 2C) 
and triacontanoic acid (Fig. 2D) were determined 
between 0 and 180 min. According to the data 
presented in Fig. 1, only total policosanol 
concentrations were evaluated in the plasma. 
Analysis of the data presented in Fig. 2 shows post-
treatment plasma policosanol and long-chain fatty 
acid response, expressed as the area under the 
curves at 0-3h after the ingestion of the policosanol 
enriched dispersion (Figs. 3A and 3B). The results 
indicate a significantly higher response in the group 
given OAEP (43690 ± 5142 ng octacosanol min 
mL–1 for OAEP compared with 30455 ± 2870 for 
NEP and 7978 ± 118 for BAEP) (Fig. 3A), which is 
similar to that obtained for triacontanol (Fig. 3B). 
Also, the group treated with OAEP elicited a 
significantly higher peak plasma octacosanol 
concentration at min 60 compared with NEP and 
BAEP (654 ± 88 ng mL–1 for OAEP compared 
with 325 ± 25 for NEP and 65 ± 18 for BAEP) 
(Fig. 3C). Comparable results were obtained for 
triacontanol (Fig. 3D). Furthermore, the peak 
plasma concentration for long-chain fatty acids in 
the OAEP group were detected at min 60, with 
octacosanoic acid being higher (P < 0.05) than 
NEP and BAEP (158 ± 19 ng mL–1 for OAEP, 81 ± 7 
Figure 1
Plasma concentration-time profile of total and non-esterified octacosanol (A) and triacontanol (B) in rats after a single oral dose  
of non-esterified policosanol (100 mg/kg) given at time zero. Insets A and B correspond to non-esterified, esterified, and total 
octacosanol and triacontanol concentrations obtained at time zero, respectively. Data are means ± SEM for three to five separate 
experiments per point. Statistical significance in insets A and B (P < 0.05) is shown by the letters identifying each experimental 
group, assessed by one-way ANOVA followed by Newman-Keuls, post-test.
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for NEP, and 5 ± 5 for BAEP) (Fig. 3C), whereas 
that of triacontanoic acid was comparable to NEP 
and higher than BAEP (P < 0.05) (Fig. 3D). 
Nevertheless, the variations in very long-chain fatty 
acid concentrations in the plasma were small in 
relation to the kinetics of their precursors.
3.3.  Comparison of plasma lipid concentrations 
in rats subjected to chronic NEP and 
OAEP administration
OAEP significantly decreased both total plasma 
cholesterol (Fig. 4A) and LDL-cholesterol (Fig. 4B) 
(40 ± 2 (n = 8) mg dL–1 and 7 ± 1 (n = 8)) compared 
to NEP (52 ± 2 and 13 ± 2) and the control group 
(51 ± 1 and 14 ± 2), respectively. Conversely, 
plasmatic HDL-cholesterol (Fig. 4C) and triglyceride 
(Fig. 4D) concentrations were not modified by NEP 
or OAEP supplementation. The total cholesterol/
HDL-cholesterol ratio (Fig. 5A) and LDL-cholesterol/
HDL-cholesterol ratio (Fig. 5B) were significantly 
(P < 0.05) decreased by OAEP compared to the 
controls and the NEP-treated rats.
3.4.  Comparison of the hepatic protein content 
of HMG-CoA red in rats subjected to 
chronic NEP and OAEP administration
The evaluation of total HMG-CoA red 
(phosphorylated + non-phosphorylated) in rat liver 
revealed comparable values in rats subjected to NEP 
and OAEP administration, and compared to control 
values (Fig. 6A). Nevertheless, phosphorylated HMG-
CoA red content significantly increased in the OAEP 
group (2.16 ± 0.3 (n = 8)) versus the NEP group 
(0.90 ± 0.11 (n =8 )) and the controls (0.38 ± 0.08 
(n = 6)) (Fig. 6B).
4. DISCUSSION 
The present investigation was focussed on 
the possible reasons regarding the controversy 
over policosanol efficacy as a hypocholesterolemic 
agent. Differences between the length of the study 
period, typical dietary habits, or ethnic diversity of 
the participants of clinical trials seem unlikely to be 
the cause of the large variation in the cholesterol 
lowering effects of this supplement. Nevertheless, 
there is agreement among the authors that a critical 
point that needs to be addressed is the availability 
of the alcohol components in the policosanol 
mixture, due to their poor absorption in the gut 
(Marrero and González-Bravo, 2001; Menéndez 
et al., 2005). Because the form of administration of 
a treatment often plays a role in determining its 
efficacy, the objective of this study was to evaluate 
policosanol chemical modifications for their 
absorption capacity. Considering the fact that 
policosanol is esterified in nature (Haim and Videla, 
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Figure 2
Plasma concentration-time profile of total octacosanol (A), octacosanoic acid (B), triacontanol (C), and triacontanoic 
acid (D) in rats after a single oral dose of either non-esterified policosanol (NEP; 100 mg/kg), oleic acid esterified 
policosanol (OAEP; 164 mg/kg), or butyric acid esterified policosanol (BAEP; 117 mg/kg) given at time zero. Data are 
means ± SEM for three to five separate experiments per point. Statistical significance (P < 0.05) is shown by the letters 
identifying each experimental group, assessed by two-way ANOVA followed by Newman-Keuls, post-test.
350 grasas y aceites, 63 (4), octubre-diciembre, 345-354, 2012, issn: 0017-3495, doi: 10.3989/gya.010612
D. HAIM, A. VALENzUELA, M. C. BrAñES, M. FUENzALIDA AND L. A. VIDELA
2008), and that phytosterols,– which are 
hypocholesterolemic phytochemical agents (Wu et 
al., 2009; Clifton, 2009) that exhibit some similar 
physical and chemical properties to policosanol, 
have demonstrated a cholesterol lowering effect 
when they are administered in their esterified 
form (Nissinen et al., 2006), we postulated that the 
esterification of policosanol could improve its 
bioavailability in relation to the non-esterified form, 
such as the commercial product. For this purpose, 
two policosanol ester families, BAEP and OAEP 
were synthesized, and the policosanol kinetics in 
plasma after a single oral dose of these esterified 
policosanol versus the non-esterified administrated 
group were compared. In addition, this work 
represents the first study incorporating the 
quantification of non-esterified, esterified, and total 
(esterified + non-esterified) policosanol in the blood.
Interestingly, a fraction higher than 95% of 
policosanol circulates as esterified alcohol in blood 
plasma, while 5% or less is found as NEP, 
proportions that were calculated from fasting rat 
plasma without the administration of policosanol. 
This difference becomes even greater after 
the administration of the policosanol dose. In 
addition, plasma concentrations of non-esterified 
octacosanol and triacontanol did not change after 
the oral dose of policosanol, regardless of the 
administration mode (NEP or OAEP). Therefore, only 
esterified policosanol concentrations increased in the 
blood after supplementation. The pharmacokinetic 
studies previously reported (Marrero and González-
Bravo, 2001; Menéndez et al., 2005, Gonzalez-Bravo 
et al., 1996) did not include a saponification step of 
plasma extracts. For this reason, the concentrations 
observed represent only non-esterified circulating 
policosanol, which explains the low values previously 
reported (Marrero and González-Bravo, 2001; 
Menendez et al., 2005, Gonzalez-Bravo et al., 1996). 
Furthermore, several studies have described the 
hydrolysis of wax as a necessary step for the 
absorption of fatty alcohols and fatty acids (Hargrove 
et al., 2004; Place, 1992). Based on this contention, 
our results suggest that a major fraction of policosanol 
is re-esterified inside the enterocyte, in agreement 
with the absorption of dietary lipids such as 
cholesterol, in which case esterification is produced 
by the catalytic action of the enzyme acyl-CoA 
cholesterol acyltransferase (Buhman et al., 2000).
The administration of OAEP demonstrated a 
major bioavailability in relation to NEP, evaluated as 
octacosanol and triacontanol plasma concentrations 
at 60 min (maximal concentration) and the respective 
areas under the time-curves. This novel and 
important finding indicates that the esterification of 
policosanol with the medium-chain monounsatured 
fatty acid oleic acid improves absorption in the 
gastrointestinal tract with respect to the available 
market product (NEP), and might represent an 
alternative way of supplementing policosanol. 
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Figure 3
Area under the time curve for octacosanol and octacosanoic acid (A) and triacontanol and triacontanoic acid (B) 
and the respective peak plasma concentrations at 60 min (C and D), corrected for values at time zero, in rats after a 
single oral dose of either non-esterified policosanol (NEP; 100 mg/kg), oleic acid esterified policosanol (OAEP; 164 
mg/kg), or butyric acid esterified policosanol (BAEP; 117 mg/kg) given at time zero (for details, see Fig. 2). Data are 
means ± SEM for three to five separate experiments per point. Statistical significance (P < 0.05) is shown by the 
letters identifying each experimental group, assessed by one-way ANOVA followed by Newman-Keuls, post-test.
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Additionally, BAEP did not alter the kinetics of 
octacosanol or triacontanol after the ingestion of 
a single oral dose, demonstrating that this 
administration form was not bioavailable in the 
animal model studied. It is postulated that the 
difference observed between the relatively high 
absorption of OAEP over that of BAEP may be 
attributed to the high stereospecificity of pancreatic 
esterases in the small intestine for long/medium-
chain fatty acids esters (Brockerhoff, 1970), rather 
than for short-chain fatty acid esters, which is the 
case of BAEP. 
Despite the fact that the active components of a 
policosanol mixture are fatty alcohols, D-003, a 
product also derived from sugarcane wax, has been 
reported to exert a cholesterol lowering effect 
in normocholesterolemic rabbits (Mendoza et al., 
2001) and in patients with hypercholesterolemia type 
II (Castaño et al., 2003). D-003 is constituted by 
long-chain fatty acids, predominantly octacosanoic 
acid, components that are the main metabolites 
produced in vivo from policosanol (Menéndez et al., 
2005). Consequently, the biologically active form of 
policosanol may include long-chain fatty alcohols 
and long-chain fatty acids. These fatty acids are 
derived from the partial oxidation of their precursors. 
Taking into account these antecedents, our study 
considered the kinetics not only of the more 
abundant alcohols of the policosanol mixture 
(octacosanol and triacontanol), but also of the 
respective fatty acids produced from their 
metabolism (octacosanoic acid and triacontanoic 
acid). The long-chain octacosanoic and triacontanoic 
fatty acids maintained low plasma concentrations in 
the time period assessed, showing a tendency 
to increase as their precursors disappeared from 
circulation, results that are consistent with the 
metabolic pathway proposed for policosanol (Haim 
and Videla, 2008; Menéndez et al., 2005; Hargrove 
et al., 2004). Nevertheless, a proportion lower than 
33% of policosanol disappearance can be explained 
by its metabolic conversion into the respective 
long-chain fatty acids. The remaining fraction of 
policosanol in circulation is likely to be taken up 
by different tissues for energetic purposes, an 
explanation based on the evidence of radioactively 
marked CO2 expiration as a terminal metabolite of 
octacosanol beta-oxidation in rats (Kabir and Kimura, 
1993).
The data presented for the NEP group are 
consistent with recent studies showing the lack of 
policosanol effect in modifying total or LDL-
cholesterol (Greyling et al., 2006; Berthold et al., 
2006; Dulin et al., 2006; Kassis and Jones, 2006; 
Francini-Pesenti et al., 2008a; Francini-Pesenti et 
al., 2008b; Kassis et al., 2007; Murphy et al., 2008), 
Figure 4
Plasma concentrations of total cholesterol (A), LDL-cholesterol (B), HDL-cholesterol (C), and triglycerides (D) in rats after  
daily administration of either vehicle for policosanol dispersion (control), non-esterified policosanol (NEP; 100 mg/kg),  
or oleic acid esterified policosanol (OAEP; 164 mg/kg) for five weeks. Data are means ± SEM for the number of animals indicated 
in parentheses. Statistical significance (P < 0.05) is shown by the letters identifying each experimental group, assessed 
by one-way ANOVA followed by Newman-Keuls, post-test.
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considering that the supplementation of rats with 
100 mg/kg body weight of NEP, the same form of 
administration in previously reported investigations, 
did not alter lipid concentrations when compared to 
the control group. Nevertheless, the OAEP group 
exhibited significantly lower concentrations of 
plasmatic LDL-cholesterol, as the primary endpoint, 
and total cholesterol, as the secondary endpoint, 
in normocholesterolemic rats after 5 weeks of 
treatment. Furthermore, OAEP administration 
achieved significant reductions in LDL-cholesterol/
HDL-cholesterol and total cholesterol/HDL-cholesterol 
ratios, relationships that are of major relevance for 
human cholesterol homeostasis. Considering that 
BAEP has no effect on plasma total cholesterol and 
LDL-cholesterol compared to OAEP, the presence of 
oleic acid from OAEP after hydrolysis and absorption 
may play a role in lowering plasma cholesterol levels. 
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Figure 5
Total cholesterol/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol ratios in rats after daily administration of either vehicle for 
policosanol dispersion (control), non-esterified policosanol (NEP; 100 mg/kg), or oleic acid esterified policosanol (OAEP; 164 mg/kg) 
for five weeks. Data are means ± SEM for the number of animals indicated in parentheses. Statistical significance (P < 0.05) is 
shown by the letters identifying each experimental group, assessed by one-way ANOVA followed by Newman-Keuls, post-test.
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Figure 6
Liver protein expression of total (A) and phosphorylated (B) 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA red) in rats 
after daily administration of either vehicle for policosanol dispersion (control), non-esterified policosanol (NEP; 100 mg/kg), or oleic acid 
esterified policosanol (OAEP; 164 mg/kg) for five weeks. Upper panels show representative blots of total HMG-CoA red (97 kDa) and 
b-actin (43 kDa) (A) and phosphorylated HMG-CoA red (98 kDa) and b-actin (B) expression using 60 mg of soluble protein. Lower 
panels show the respective densitometric quantification expressed as total HMG-CoA red/b-actin (A) and phosphorylated HMG-CoA 
red/b-actin (B) ratios to compare lane-to-lane equivalence in total protein content. Data are means ± SEM for the number of animals 
indicated in parentheses. Statistical significance (P < 0.05) is shown by the letters identifying each experimental group, assessed by 
one-way ANOVA followed by Newman-Keuls, post-test.
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However, previous studies have reported (i) the 
presence of comparable levels of plasma cholesterol 
in postmenopausal women before and after 
consumption of high oleic acid sunflower oil for 28 
days (Sánchez-Muniz et al., 2002); and (ii) the lack of 
effects of the partial exchange of palmitic acid for oleic 
acid in healthy, normocholesterolemic humans (Ng 
et al.,1992; Choudhury et al., 1995) and cebus 
monkeys (Hayes and Khosla, 1992), suggesting that 
oleic acid is neutral with respect to plasma cholesterol 
homeostasis. 
regarding the mechanisms underlying the 
hypocholesterolemic action of policosanol, Singh et 
al. (Singh et al., 2006) found increased amounts of 
phosphorylated AMP-kinase after the incubation 
of hepatoma cells with policosanol. These authors 
postulated that policosanol inactivates HMG-CoA 
red by promoting its phosphorylation by AMP-kinase, 
in agreement with data reported by Oliaro-Bosso et 
al. in HUVEC and HepG2 cells (Oliaro-Bosso et al., 
2009). Despite the evidence that phosphorylated 
AMP-kinase decreases HMG-CoA red activity, this 
kinase plays a central role in the regulation of energy 
homeostasis, regulating several enzymes involved 
in glucose and lipid metabolism (Wong et al., 2009). 
Therefore, we decided to quantify directly the 
phosphorylated HMG-CoA red, instead of AMP-
kinase, in order to establish a possible relationship 
between policosanol administration and HMG-CoA 
red activity. The data presented indicate that 
supplementation with NEP or OAEP did not 
significantly alter the amount of total HMG-CoA red 
protein compared to control values, whereas OAEP 
increased the phosphorylated form of the enzyme, in 
agreement with the reduction in the total and LDL-
cholesterol concentrations in serum, an effect that is 
not observed for NEP.
5. CONCLUSION
The present study shows that OAEP is more 
bioavailable and effective than NEP in reducing plasma 
total and LDL-cholesterol in normocholesterolemic 
rats, in association with HMG-CoA red inactivation 
through OAEP-induced phosphorylation. Alternative 
mechanisms for the cholesterol-lowering action of 
OAEP, namely, enhancement in both bile acid 
excretions due to 7-a-hydroxylase up-regulation and/or 
clearance of LDL-cholesterol due to higher cell-
membrane LDL receptor availability, are currently 
under study in our laboratory. Considering that this is 
the first investigation using an esterified policosanol in 
replacement of the conventional mixture (NEP), 
additional studies are needed to fully understand their 
digestion, absorption, and metabolism in the body. 
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